Situation summary

In the Region of the Americas, between epidemiological week (EW) 1 and EW 22 of 2019, a total of 1,191,815 cases of dengue (118.5 cases per 100,000 population\(^1\)) have been reported, of which 546,589 (46%) were laboratory-confirmed and 5,599 (0.47%) were classified as severe dengue. The reported case-fatality rate was 0.02%.

The number of cases reported during this period (EW 1 to EW 22 of 2019) was higher than the annual totals reported during the most recent two years (2017-2018), but lower than the annual totals reported during 2015-2016. The proportion of cases of severe dengue reported thus far in 2019 is higher than the annual proportions reported during 2016-2017, but lower than the annual proportions reported during the previous 10 years (2006-2015) (Figure 1).

Following almost two years of low dengue transmission, there has been an increasing trend in both the number of reported dengue cases and the number of reported severe dengue cases since the end of 2018 and beginning of 2019.

Although the overall dengue case-fatality rate\(^2\) reported in the Region of the Americas between EW 1 and EW 22 of 2019 is the lowest in the past 10 years (Figure 2), an increase in case-fatality rates has been observed among under 15-year-olds and adults aged 75 years or older in Brazil, with DENV 2 as the predominant serotype.

The four dengue virus serotypes (DENV 1, DENV 2, DENV 3, and DENV 4) are currently circulating simultaneously in the Region of the Americas, which increases the risk of occurrence of severe cases along with the subsequent burden on healthcare services. During 2019, two countries have reported circulation of all four serotypes (Guatemala and Mexico), while four countries have reported circulation of three serotypes: Colombia (DENV 1, DENV 2, and DENV 3), Paraguay (DENV 1, DENV 2, and DENV 4), Peru (DENV 2, DENV 3, and DENV 4), and Venezuela (DENV 1, DENV 2, and DENV 3).

Brazil, Colombia, and Honduras, which account for 93% of the total number of reported cases in the Region of the Americas, have reported an increase in the number of cases between EW 1 and EW 22 of 2019 compared to the same period in 2018.

\(^1\) To calculate the population in the Americas, the at-risk population was considered; therefore, the populations of Canada, continental Chile, and Uruguay have been excluded.

\(^2\) Dengue mortality was calculated using the number of dengue deaths among the total number of reported dengue cases.
Figure 1. Reported number of dengue cases and the proportion of severe dengue cases, by year of report. Region of the Americas, 1999-2019 (up to EW 22).

Figure 2. Reported number of dengue cases and case-fatality rates, by year of report. Region of the Americas, 1999-2019 (up to EW 22).

Sources for Figures 1 and 2: Data uploaded to the Health Information Platform for the Americas (PLISA, PAHO / WHO) by the Ministries and Institutes of Health of the countries and territories of the Region. For Brazil, Colombia, and Guatemala, data was provided by the International Health Regulations National Focal Points.
The four countries with the highest incidence rates of reported cases up to EW 22 of 2019 are Brazil, Nicaragua, Colombia, and Honduras (Table 1). Brazil has the highest reported incidence rate in the Region (505.5 cases per 100,000 population) and a case-fatality rate of 0.03%. Nicaragua has reported an incidence rate of 441.9 cases per 100,000 population but has one of the lowest case-fatality rates in the Region. Colombia, which has the third highest incidence rate, has reported an increase in cases since EW 42 of 2018, has been in the epidemic zone of the endemic channel since EW 8 of 2019, and has a case-fatality rate of 0.04%. Honduras, which ranks fourth among the countries with the highest incidence rates, has reported a sustained increase in cases since EW 44 of 2018, is in the epidemic zone of the endemic channel, and has a case-fatality rate of 0.3%, which is the highest reported in the Region thus far in 2019.

Table 1. Incidence rates and number of dengue cases, proportion of severe dengue (SD) cases, case-fatality rates, and serotypes, in 10 selected countries of the Region. EW 1 to EW 22 of 2019.

<table>
<thead>
<tr>
<th>Country</th>
<th>Incidence rate (cases per 100,000)</th>
<th>Number of cases</th>
<th>Proportion of SD (%)</th>
<th>Case-fatality rate (%)</th>
<th>Serotypes reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brazil*</td>
<td>505.5</td>
<td>1,054,015</td>
<td>0.06</td>
<td>0.03</td>
<td>1.2</td>
</tr>
<tr>
<td>Nicaragua</td>
<td>441.9</td>
<td>27,779</td>
<td>N/A</td>
<td>0.01</td>
<td>2</td>
</tr>
<tr>
<td>Colombia</td>
<td>170.9**</td>
<td>45,622</td>
<td>1.13</td>
<td>0.04</td>
<td>1,2,3</td>
</tr>
<tr>
<td>Honduras</td>
<td>113.5</td>
<td>10,390</td>
<td>3.59</td>
<td>0.29</td>
<td>1.2</td>
</tr>
<tr>
<td>Bolivia</td>
<td>40.7</td>
<td>4,560</td>
<td>0.20</td>
<td>0.15</td>
<td>1.2</td>
</tr>
<tr>
<td>Guatemala</td>
<td>24.0</td>
<td>4,233</td>
<td>0.35</td>
<td>0.28</td>
<td>1,2,3,4</td>
</tr>
<tr>
<td>Peru</td>
<td>14.7</td>
<td>4,772</td>
<td>0.84</td>
<td>0.19</td>
<td>1,2,4</td>
</tr>
<tr>
<td>Mexico</td>
<td>14.4</td>
<td>18,835</td>
<td>1.11</td>
<td>0.08</td>
<td>1,2,3,4</td>
</tr>
<tr>
<td>Dominican Republic</td>
<td>12.8</td>
<td>1,391</td>
<td>2.59</td>
<td>0.00</td>
<td>1,3</td>
</tr>
<tr>
<td>Venezuela</td>
<td>11.2</td>
<td>3,636</td>
<td>0.66</td>
<td>0.22</td>
<td>1,2,3</td>
</tr>
</tbody>
</table>

* To calculate the incidence rate, proportion of severe dengue cases, and case-fatality rate, discarded cases were excluded.

** Calculation using the at-risk Colombian population (26,689,338 persons)

Sources: Data uploaded to the Health Information Platform for the Americas (PLISA, PAHO / WHO) by the Ministries and Institutes of Health of the countries and territories of the Region. For Brazil, Colombia, and Guatemala, data was provided by the International Health Regulations National Focal Points.
Advice to Member States

The Pan American Health Organization / World Health Organization (PAHO/WHO) reiterates the recommendations provided to Member States in the 21 November 2018 Epidemiological Alert³ and the 22 February 2019 Epidemiological Update⁴.

The following is a summary of the key recommendations regarding outbreak preparedness and response, case management, laboratory diagnosis, risk communication, and integrated vector management.

**Outbreak preparedness and response**

As part of outbreak preparedness and response, it is recommended that Member States:

- strengthen disease surveillance, including laboratory diagnosis;
- review emergency plans;
- strengthen and intensify vector surveillance and control;
- ensure that healthcare professionals are properly trained for appropriate clinical diagnosis and clinical management of patients with dengue or other arboviruses, with a special focus on age groups and at-risk groups with the highest case-fatality rates;
- involve the community in prevention and control activities;
- ensure performance of the outbreak response is monitored and systematized, including the establishment of a situation room; and
- adapt risk communication according to the epidemiological scenario.

In countries with presence of the vectors but without dengue virus circulation, preparedness and response plans should focus on strategies to reduce the risk of transmission. Rapid investigation of all clinically suspected cases should be carried out as well as laboratory testing to confirm the presence of the dengue virus.

**Situation Room**

The situation room is a key tool for informed decision making, wherein information is analyzed through multi-disciplinary teams to support health management. It has a key role in the response to outbreaks and emergencies situations. In the case of dengue, the situation room is typically where key aspects of the inter-sectoral response are tracked,


bringing together information from all involved sectors. The activities carried out in the situation room include, but are not limited to:

- Analysis and continuous systematic assessment of the current and prospective situation.

- Integration of epidemiological information, including laboratory diagnosis, vector control, and case management, aimed at:
  - Early detection of cases and outbreaks.
  - Monitoring trends and incidence.
  - Understanding the dynamics of viral circulation.

- Guide and maintain data collection, including data quality control.

- Monitor actions and impact of intervention measures.

- Produce periodic concise, operationally focused situation reports to support coordination of the emergency or outbreak response. The situation report should:
  - Provide a snapshot of the current needs, response, and gaps during outbreaks or emergency situations.
  - Be a tool for mobilizing resources.

- Manage key aspects of logistics for the ongoing prevention and control response.

**Case management**

While the clinical manifestations of the disease are complex, treatment is relatively simple, inexpensive, and very effective in saving lives if timely and adequate management is provided. Early recognition of warning signs at different stages of the disease is critical in order to provide the necessary health care, and therefore prevent progression to severe disease.

When the clinical diagnosis is suggestive of dengue, chikungunya, or Zika, patients (particularly children), should be managed as a case of dengue and monitored daily to detect warning signs of severe illness, especially during the critical phase of the disease\(^5\).

In cases of dengue without warning signs, patients\(^6\) should receive information about these signs for timely identification of warning signs and for seeking medical assistance.

**Clinical management and treatment of patients suspected with dengue should be initiated without waiting for laboratory confirmation of dengue. Initial clinical diagnosis is sufficient to offer timely and adequate medical care and treatment.**

---


\(^6\) Or parents or guardians, in the case of children.
Organization of healthcare services and referral of patients

The main objective of the prevention and control measures during dengue outbreaks is to prevent deaths. Consequently, timely and adequate care of patients, as well as strengthening coordination between different health areas and services, should be promoted. If dengue cases increase, the healthcare network should consider expanding healthcare services and ensuring sufficient supplies, equipment, medication, access to clinical tests, and hospital beds; adequate patient monitoring and the use of patient tracking forms should also be ensured.

The primary level of healthcare is key in the management of dengue cases, as this is the level in which the first contact with patients occurs and where most cases receive medical attention. Therefore, it is recommended that the primary level of healthcare:

- Have sensitized and trained personnel for the triage of cases upon arrival at the healthcare service. These personnel should provide instructions and guidance to patients and/or family members on how to identify warning signs of dengue and seek the nearest healthcare service as soon as these signs occur.

- Have healthcare personnel trained to observe and detect patients who present with warning or severe signs in waiting, in order to ensure immediate care and reduce waiting time.

- Establish dengue units for the management of dengue cases with warning signs.

- Ensure continuous clinical monitoring of patients with specialized medical needs, co-morbidities, pregnant women, concomitant conditions, or persons whose social situation makes it difficult to access the necessary care (such as persons living in remote places, refugees, displaced persons, among others).

- Establish referral and counter-referral systems for severe dengue cases between different healthcare levels. Severe cases of dengue should be referred to a higher-level unit (secondary or tertiary level), after stabilization of the patient and coordination between healthcare units.

- All units of this level should have flowcharts and guidelines for the clinical management of dengue, available to all medical and paramedical personnel, for any necessary consultation during medical attention of patients.

The secondary and tertiary levels of healthcare should be designed for the management of severe cases of dengue. Thus, overwhelming these units is avoided and specific clinical care can be provided to patients requiring highly specialized care.

As part of the organization of the healthcare systems in emergency situations or outbreaks, the following is necessary:

- A group of highly specialized physicians should be established to provide medical guidance on diagnosis and management of dengue cases, mainly to support physicians in remote areas (peripheral areas).
• A hotline for consultation with a trained physician, particularly for healthcare personnel in peripheral areas.

• The healthcare personnel in healthcare units should have access to clinical guidelines and flowcharts for the care of dengue cases.

• Continuous education should be maintained in healthcare units, particularly regarding the management of severe and difficult-to-treat cases as well as the analysis of dengue deaths.

A timely approach, the correct classification of cases, and proper case management are key elements of healthcare to prevent patient deaths due to dengue. A delay in medical care for these cases is often related to the cause of death.

Laboratory diagnosis

Diagnosis and etiological confirmation of dengue infection can be performed through virological assays (viral isolation, detection of genetic material, detection of NS1 protein, or immunohistochemistry) or by serological tests for the detection of IgM antibodies.

Virological diagnosis

• Molecular detection: During the first 5 days from the onset of symptoms (acute phase, viremic period), viral RNA from a serum sample can be detected using molecular techniques such as conventional or real-time reverse transcription polymerase chain reaction (RT-PCR). A positive PCR result (with appropriate controls) confirms the diagnosis.

• Viral isolation: Can be performed by intracerebral inoculation in mice or in cell culture. However, due to its complexity, this is rarely used as a routine diagnostic test and is recommended only for research or characterization to complement public health surveillance.

• NS1 Protein: The nonstructural protein 1 (NS1) of the dengue virus can be detected by ELISA up to 9 days after the onset of symptoms. However, since it is a protein produced at an early stage of infection, it is most likely detected between the first 3 to 5 days after the onset of symptoms.

• Post-mortem diagnosis: In fatal cases, it is recommended to take tissue samples (preferably liver, followed by spleen and kidney) in buffered formalin for histopathological and immunohistochemical assay. Additionally, molecular methods (RT-PCR) from fresh tissue samples (taken in dry tube and maintained in refrigeration), or preserved in paraffin, can also be used for the confirmation of fatal cases associated with dengue or to conduct differential diagnosis.

Serological diagnosis

A positive IgM result using the ELISA technique (MAC-ELISA or any other immunoassay) in a sample taken after the fifth day of symptom onset is presumptive of recent dengue
infection. A single serum in the acute phase is considered presumptive, so it is recommended that a second sample be taken between one and two weeks after the first sample to demonstrate seroconversion (negative to positive) or an increase up to four times the antibody titer (with one quantitative assay).

Cross-reactivity with other flaviviruses (mainly in secondary infections) should be considered in areas where co-circulation with other flaviviruses (e.g., Zika, yellow fever, St. Louis Encephalitis, etc.) is documented and where there is a likelihood that the population has been previously infected.

Therefore, the detection of antibodies for other flaviviruses (e.g., IgM for Zika) by ELISA should be conducted in parallel. A positive result for dengue IgM in the absence of IgM for Zika (negative) is presumptive of dengue infection, while a negative IgM result for dengue with Zika-positive IgM will be presumptive of infection by the latter. However, a positive result for the two assays only indicates a recent flavivirus infection, and therefore, it will not be possible to confirm an etiologic agent. For this reason, results should be analyzed while also considering the clinical characteristics and the epidemiological history of the case.

**Rapid tests**

Immunochromatography-based rapid tests have been widely used for the diagnosis of dengue. However, in addition to the challenges observed by cross-reactivity, these types of tests have shown low sensitivity so the negative predictive value is very low, and a negative result will not rule out a case. Due to this, implementation and use of these types of tests for public health purposes should be carefully assessed.

**Risk Communication**

Risk communication and information to the public is essential during outbreaks to reduce adverse impact, decrease domestic breeding sites, and for affected persons to seek timely medical assistance, and therefore prevent severe cases and deaths from dengue. Communication messages should focus on the identification of warning signs and obtaining timely medical assistance.

In addition, communication campaigns should raise public awareness on the importance of vector control interventions at home, identification of febrile cases, and special measures for vector control, specifically the control of intra- and peri-domiciliary breeding sites, and personal protection.

**Integrated vector management**

The objective of integrated vector management is to improve efficiency and achieve sustainability in vector prevention and control actions, and includes the following:

- Selection of control methods based on knowledge of the biology of the vector, disease transmission, and morbidity.
- Use of multiple interventions, often in combination and in a synergistic and synchronized manner.
• Collaboration of the health sector with other public and private sectors linked to the management of the environment that have work which impacts or could impact reduction of the vector.

• Integration of individuals, families, and other key partners (education, finance, tourism, water and sanitation, and others).

• Establishment of a legal framework that permits an integrated and intersectoral approach.

Given the high infestation by *Aedes aegypti* and the presence of *Aedes albopictus* in the Region, prevention and control measures should be aimed at reducing the density of the vector, with local community acceptance and collaboration in adopting such measures.

Prevention and control measures to be implemented by national authorities should include the following:

• Strengthen environmental management actions, mainly by eliminating vector breeding sites in every home and in common areas of neighborhoods and cities (parks, schools, cemeteries, etc.).

• Organize intensive environmental sanitation campaigns for the elimination of breeding sites in specific areas where routine garbage collection has been interrupted.

• Implement breeding site control measures through the use of physical, biological, and/or chemical methods, with the active involvement of individuals, family members and the community.

• Identify the areas at high-risk of transmission (risk stratification) and prioritize those where there are larger concentrations of people (schools, transportation terminals, hospitals, health centers, etc.). In these areas, the presence of mosquitoes must be removed within a diameter of at least 400 meters. Special attention should be given to health units, so that these are free of the presence of the vector and its breeding sites so that they do not become points of exposure for the virus.

• In areas where active transmission is detected, it is suggested to use adulticide treatment (mainly through spraying) to remove infected adult mosquitoes in order to stop and interrupt transmission. It is important to take into account that this action is of exceptional nature and only effective when executed by properly trained personnel following internationally accepted technical guidelines and when performed concomitantly to other proposed actions. Spraying and elimination and/or control of vector breeding sites within households is the main action to interrupt transmission when it intensely occurs. The greatest impact for the elimination of infected adult mosquitoes (active transmission) is achieved with intra-domiciliary spraying, using individual equipment.

• Select appropriate insecticides (in accordance with PAHO/WHO recommendations), verify the product formula, and consider the susceptibility of mosquito populations to that insecticide.
• Maintain and use spraying equipment in an appropriate manner and maintain insecticide reserves.

• Ensure intensified monitoring actions (quality control) of field work operators both during larval control and during adulticide treatment (spraying).

• Emphasize integrated (simultaneous or coordinated) actions for vector control, in space and time (adulticidal and larval control by trained personnel, coupled with sanitation and the promotion of community actions), is essential to achieve a greater impact in the shortest time possible.

**Personal Prevention Measures**

Patients infected with the dengue virus are the reservoir of infection for other people both at home and in the community. Therefore, public health measures to minimize the exposure of patients to mosquitoes are critical in preventing the spread of the virus and, consequently, of the disease.

Patients, other household members, and the affected community must be informed about the risk of transmission to others and ways to minimize this risk by reducing the vector population and human-vector contact.

The following actions are recommended to minimize patient-vector contact:

• The patient must rest under mosquito nets, impregnated, or not, with insecticide.

• The patient, as well as other members of the household, must wear long sleeves (when ill persons are in the house) to cover extremities.

• Repellents containing DEET, IR3535, or Icaridine can be applied to exposed skin or clothing and its use must be in strict accordance with the instructions on the product label.

• Use wire-mesh/mosquito nets on doors and windows.

These personal prevention measures are also effective in preventing the transmission of the virus to healthy people.
Sources of information

1. PAHO / WHO Health Information Platform for the Americas (PLISA). Available at: https://bit.ly/2Pes0li

2. Brazil International Health Regulations (IHR) National Focal Point (NFP) report to PAHO/WHO received by email.

3. Colombia International Health Regulations (IHR) National Focal Point (NFP) report to PAHO/WHO received by email.

4. Guatemala International Health Regulations (IHR) National Focal Point (NFP) report to PAHO/WHO received by email.

5. Honduras International Health Regulations (IHR) National Focal Point (NFP) report to PAHO/WHO received by email.

6. Mexico International Health Regulations (IHR) National Focal Point (NFP) report to PAHO/WHO received by email.

Bibliography
